59 related articles for article (PubMed ID: 15472167)
1. A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure.
Orgiana G; Pinna G; Camedda A; De Falco V; Santoro M; Melillo RM; Elisei R; Romei C; Lai S; Carcassi C; Mariotti S
J Clin Endocrinol Metab; 2004 Oct; 89(10):4810-6. PubMed ID: 15472167
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
[TBL] [Abstract][Full Text] [Related]
3. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
4. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
Da Silva AM; Maciel RM; Da Silva MR; Toledo SR; De Carvalho MB; Cerutti JM
J Clin Endocrinol Metab; 2003 Nov; 88(11):5438-43. PubMed ID: 14602786
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
6. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
7. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.
Skinner MA; Moley JA; Dilley WG; Owzar K; Debenedetti MK; Wells SA
N Engl J Med; 2005 Sep; 353(11):1105-13. PubMed ID: 16162881
[TBL] [Abstract][Full Text] [Related]
9. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
10. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.
Nishikawa M; Murakumo Y; Imai T; Kawai K; Nagaya M; Funahashi H; Nakao A; Takahashi M
Eur J Hum Genet; 2003 May; 11(5):364-8. PubMed ID: 12734540
[TBL] [Abstract][Full Text] [Related]
11. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
[TBL] [Abstract][Full Text] [Related]
12. Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia.
Lima J; Teixeira-Gomes J; Soares P; Máximo V; Honavar M; Williams D; Sobrinho-Simões M
J Clin Endocrinol Metab; 2003 Oct; 88(10):4932-7. PubMed ID: 14557476
[TBL] [Abstract][Full Text] [Related]
13. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
14. A RET C634R mutation in a Thai female with multiple endocrine neoplasia type 2A.
Sunthornyothin S; Sinthuwiwat T; Shotelersuk V
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S472-6. PubMed ID: 12930027
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
[TBL] [Abstract][Full Text] [Related]
16. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
17. Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma.
Huang SC; Torres-Cruz J; Pack SD; Koch CA; Vortmeyer AO; Mannan P; Lubensky IA; Gagel RF; Zhuang Z
J Clin Endocrinol Metab; 2003 Jan; 88(1):459-63. PubMed ID: 12519890
[TBL] [Abstract][Full Text] [Related]
18. A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease.
Dvoráková S; Dvoráková K; Malíková M; Skába R; Vlcek P; Bendlová B
J Pediatr Surg; 2005 Jun; 40(6):e1-6. PubMed ID: 15991157
[TBL] [Abstract][Full Text] [Related]
19. Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin.
Vierhapper H; Bieglmayer C; Heinze G; Baumgartner-Parzer S
Thyroid; 2004 Aug; 14(8):580-3. PubMed ID: 15320968
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis of MEN2-associated tumors.
Koch CA
Fam Cancer; 2005; 4(1):3-7. PubMed ID: 15883703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
